fbpx

QQQ
-8.37
382.20
-2.24%
BTC/USD
-3856.65
43881.17
-8.08%
DIA
-5.07
350.71
-1.47%
SPY
-7.26
448.66
-1.64%
TLT
+ 1.26
147.91
+ 0.84%
GLD
+ 1.30
162.47
+ 0.79%

Cannabis Analyst: March Earning Season May Not Push Canadian LPs, But There Are Other Catalysts

April 10, 2021 5:17 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Analyst: March Earning Season May Not Push Canadian LPs, But There Are Other Catalysts

The global pandemic and following lockdowns impacted almost every sector of the economy. And the Canadian cannabis industry was no exception.

Adult-use cannabis retail sales in the country experienced sequential growth of barely 4% in the first quarter of 2021, compared to the 12% surge seen in Q4 2020, and 31% in Q3 2020. This development, however, could only be “partly explained by the COVID lockdown,” according to Cantor Fitzgerald’s analyst Pablo Zuanic.  

The Thesis

With the Q1 earnings season approaching, some may expect it to have a positive influence on cannabis operators. But the analyst doubts it. In fact, he notes, the Canadian Marijuana Index has fallen by 50% since its February peak. During the same period, the U.S. Marijuana Index dropped by 33%, while the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) only lost 23% of its value.

The drop in the Canadian Index can only partly be explained by the volatility around Sundial Growers (NASDAQ:SNDL), which dropped by 66% since February, and Tilray Inc. (NASDAQ:TLRY), which fell 69%, as these two stocks only offer U.S. listings, but not Canadian listings, explained the analyst.

Among other contributors to the pullback, the analyst highlighted “Question marks about the timing of deregulation in the US, profit taking, and concerns about the cal 1Q earnings season.”

But there are other factors to feel bullish on the Canadian market outlook. These include frequent mergers and acquisitions; news on overseas markets that are about to legalize cannabis, such as Mexico; and better retail trends after the recent setback due to the pandemic-caused lockdowns, noted Zuanic.

“The larger companies are true plays on the global cannabis industry.”

The analyst issued an ‘Overweight’ rating on Aphria (NASDAQ:APHA), Organigram (NASDAQ:OGI) and Auxly Cannabis Group (OTC:CBWTF), maintaining estimates and ratings for the other companies in the group.

Photo by Ryan Lange on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Canadian Cannabis Producers Are Dependent On Value Flower: Analyst

Canadian Cannabis Producers Are Dependent On Value Flower: Analyst

Canadian licensed cannabis producers have been faced with challenges imposed by ongoing price deflation, COVID-19 lockdowns and uncertainty over whether and when U.S. federal legalization will occur. As a result, some Canadian cannabis companies have become dependent on value flower, according to a Cantor Fitzgerald analyst.  read more
Canadian Cannabis: Why This Penny Stock Is 'Arguably The Best Value'

Canadian Cannabis: Why This Penny Stock Is 'Arguably The Best Value'

Top Canadian cannabis stocks, including Tilray Inc (NASDAQ: TLRY), Aphria Inc (NASDAQ: APHA) and Aurora Cannabis Inc (NYSE: ACB), hav read more
Why This Organigram Analyst Says It's A Good Time To Buy Cannabis Stock

Why This Organigram Analyst Says It's A Good Time To Buy Cannabis Stock

Cannabis company Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) posted second-quarter earnings last week, with gross reve read more
Tilray Analysts On The Sidelines Despite Solid Earnings

Tilray Analysts On The Sidelines Despite Solid Earnings

Canadian cannabis companies Tilray Inc. (NASDAQ: TLRY) and Aphria Inc. (NASDAQ: APHA) have agreed to read more